Biotech goes to the White House
What was initially planned as a scolding on the price of medicine instead became a sort of White House pitch meeting for biopharma CEOs, as President Trump pressed some of the biggest names in the drug business to figure out who could deliver him a coronavirus treatment the fastest.
As STAT’s Lev Facher reports, yesterday’s pharma summit found Trump listening to explanations of mRNA, adenovectors, and recombinant DNA from the likes of Johnson & Johnson, Moderna Therapeutics, and Gilead Sciences. His chief interest seemed to be speed, and he more than once played CEOs off one another as if their development timelines were bids that could be negotiated.
Read more.
Meanwhile, if you’re curious just who’s doing what when it comes to biopharma and the novel coronavirus, we’ve compiled a cheat sheet of vaccines and therapeutics in development.
As STAT’s Lev Facher reports, yesterday’s pharma summit found Trump listening to explanations of mRNA, adenovectors, and recombinant DNA from the likes of Johnson & Johnson, Moderna Therapeutics, and Gilead Sciences. His chief interest seemed to be speed, and he more than once played CEOs off one another as if their development timelines were bids that could be negotiated.
Read more.
Meanwhile, if you’re curious just who’s doing what when it comes to biopharma and the novel coronavirus, we’ve compiled a cheat sheet of vaccines and therapeutics in development.
.png)
No hay comentarios:
Publicar un comentario